Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Urinary Bladder Neoplasms 2Urinary Tract Infections 1Tissue Adhesions 1Stomach Neoplasms 1Polyps 1Non-Muscle Invasive Bladder Neoplasms 1Neutropenia 1Neoplasms 1Myoma 1Multiple Myeloma 1Infections 1Hematologic Neoplasms 1Hearing Loss 1Febrile Neutropenia 1Endometritis 1Ear Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Cystitis 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Ofloxacin × Clear all
NCT00002850 2015-11-11

Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy

University of Rochester

Phase 3 Completed
212 enrolled 12 charts
Plasma cell

Infections, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡